Mizzou Researchers Identify Genetic Markers to Predict Early Follicular Lymphoma Recurrence

Researchers at the University of Missouri School of Medicine have identified genetic and molecular markers that can predict early recurrence in patients with Follicular Lymphoma (FL). This significant discovery holds promise for revolutionizing individualized cancer care for FL patients.

Follicular Lymphoma is a type of blood cancer and a form of non-Hodgkin's lymphoma. While approximately 80% of FL patients have a survival rate exceeding 10 years, the remaining 20% experience a quickly recurring or more aggressive form of the cancer.

The study revealed that over 10 genetic or molecular markers, primarily genetic mutations, were found to be unique to patients whose FL cancer relapsed early. These crucial biomarkers are potentially detectable at the time of initial diagnosis, according to study author Cherian Verghese.

Identifying patients prone to early relapse can improve individualized cancer care, optimize patient outcomes, and reduce the necessity for excessive imaging and surveillance testing for other patients with FL.

The research involved analyzing genetic and molecular data from relapsed FL patients over a 14-year period, from 2009 to 2023. This approach directly addresses limitations of previous prognostic models, which often relied on less reliable clinical predictors such as cancer stage or tumor grade.

By pinpointing patients at higher risk, this research can improve individualized cancer care, optimize patient outcomes, and reduce the necessity for excessive imaging and surveillance testing for other patients with FL. Ultimately, this can lead to substantial cost savings and increased efficiency for both patients and healthcare providers.

The findings were published in the American Journal of Clinical Oncology in an article titled "Surveillance Strategies in Follicular Non-Hodgkin's Lymphoma's Using Molecular and Genetic Markers Improve Cost-efficiencies Over Routine Imaging Studies." Key contributors from the Mizzou study include Cherian Verghese, Urja Nagadia, and Niravkumar Brahmbhatt, among others.